IKT Insider Trading Activity and SEC Form 4 Filings
IKT insider trading summary
Over the past 12 months, insiders at Inhibikase Therapeutics, Inc. (IKT) reported 3 open-market purchases worth $9.0M by 3 insiders and no sales on SEC Form 4. Net insider buying was $9.0M.
Latest IKT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 21, 2025 | Frank M. Sands | 10% Owner | Buy | $3.0M (2,068,965 @ $1.45) |
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10% Owner | Buy | $3.0M (2,068,965 @ $1.45) |
| Nov 21, 2025 | Sands Capital Alternatives, LLC | 10% Owner | Buy | $3.0M (2,068,965 @ $1.45) |
| Oct 21, 2024 | Amit Munshi | Insider | Buy | $500K (365,000 @ $1.37) |
| Oct 21, 2024 | Roberto Bellini | Insider | Buy | $2.0M (1,460,000 @ $1.37) |
| Oct 21, 2024 | Arvind Kush | Insider | Buy | $199K (145,000 @ $1.37) |
| Aug 16, 2022 | Milton H. Werner | President and CEO | Buy | $4K (5,000 @ $0.80) |
| May 27, 2022 | Milton H. Werner | President and CEO | Buy | $5K (5,000 @ $0.98) |
| May 20, 2022 | Milton H. Werner | President and CEO | Buy | $6K (10,000 @ $0.60) |
| May 19, 2022 | Joseph Frattaroli | Chief Financial Officer | Buy | $3K (3,948 @ $0.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.